Background. Treatment of inflammatory kidney diseases with systemic high-dose glucocorticoids (GCs) has severe side effects. Liposomal encapsulation could facilitate local delivery of GCs to the inflamed kidney, as liposomes encapsulate their payload until extravasation at sites of inflammation, potentially resulting in local bioactivity. Our aim was to evaluate the ability of liposomes to accumulate locally after renal ischaemia-reperfusion injury in the rat and to study its effect on macrophages. Methods. In vitro, human macrophages were incubated with fluorescent liposomes, liposomal prednisolone, prednisolone, empty liposomes or saline. Uptake was studied microscopically and treatment effect was assessed by interkeukin 6 (IL-6) enzyme-linked immunosorbent assay. The mechanism of action was evaluated by analysing GC receptor activation by microscopy and quantitative polymerase chain reaction (qPCR). In vivo, rats were subjected to ischaemia-reperfusion injury and were injected intravenously with fluorescent liposomes, liposomal prednisolone, prednisolone, empty liposomes or saline. Uptake was measured by the FLARE camera and the treatment effect by immunohistochemistry for myeloid cells and qPCR for inflammatory markers.
GR in healthy non-target tissues. In addition, such a change in biodistribution will potentially also result in increased GC levels within the target tissue (e.g. the kidney) when compared with systemic delivery of conventional GCs.
Nanoparticle-based delivery using liposomes has emerged as a novel strategy to facilitate selective drug delivery to inflamed tissues [7] . Liposomes are composed of phospholipids, which spontaneously self-assemble into vesicular structures when dispersed in aqueous media. The size of the liposomes (100-500 nm) facilitates local uptake in inflamed tissue [8, 9] , as the liposomes employ the increased permeability of the endothelium in inflamed tissues to extravasate, whereas they cannot pass the normal endothelium in healthy tissues. In addition, PEGylation of the liposomes increases their circulatory time [10] , which allows for the payload to be retained until extravasation, where interaction with phagocytic cells is possible.
The latter is essential to mediate a local effect in the inflamed tissue, since the cellular component of the infiltrate, e.g. phagocytic cells such as macrophages, can actively take up large particles [11] . Importantly, since macrophages are widely recognized as pivotal modulators of immune responses (harbouring both pro-and anti-inflammatory properties) [12] [13] [14] , macrophages are the primary target for local anti-inflammatory treatment with GC-containing liposomes.
Previous preclinical studies in rheumatoid arthritis have illustrated the potency of liposomal prednisolone, as complete remission was achieved upon a single injection, which was superior to the effect of an equal dose of conventional prednisolone [15] . Subsequently, encouraging results were obtained in an animal model of arteriovenous fistula failure, where liposomal prednisolone rapidly abolished the local inflammatory response in the vasculature [16] .
In the present study, we evaluated the effects of liposomal prednisolone on acute inflammatory conditions in the kidney. For this purpose, we used the well-established rat model of ischaemia-reperfusion injury (IRI) [17] . The main aims of this study were to investigate local accumulation of liposomes in the inflamed tissue after systemic injection and to study the effect of liposomal prednisolone on the inflammatory state of the macrophage, both in vivo and in vitro. 
Cell culture
Human primary pro-and anti-inflammatory macrophages, human umbilical vein endothelial cells (HUVECs), human renal epithelial cells (HK2), human monocytic cells (THP-1) [American Type Culture Collection (ATCC), Manassas, VA, USA] and mouse macrophage cells (RAW 264.7) (ATCC) were cultured according to protocol. Differentiation of macrophages was determined by fluorescence-activated cell sorting (FACS) using fluorescein isothiocyanate (FITC)-conjugated anti-CD14 and PE-conjugated anti-CD163 (both from BD Biosciences Pharmingen, San Diego, CA, USA).
Liposomal formulations
PEGylated liposomal prednisolone was prepared as described previously [16] . Fluorescent liposomes were labelled with either Alexa 750 or Cy5.5.
Cellular uptake of liposomes in vitro
Pro-and anti-inflammatory macrophages, HUVEC, HK2 and THP-1 cells were exposed to fluorescent liposomes and stained with PKH67 (1:5000, Sigma-Aldrich, St Louis, MO, USA) and Hoechst 1:10 000 in PBS (Invitrogen, Waltham, MA, USA).
Activation of the GR
RAW 264.7 macrophages were incubated for 12 h on prednisolone (10 mg/mL) or 20 h on liposomal prednisolone (10 mg/ mL) or left untreated. The GR was visualized using immunocytochemistry. In a similar set-up the messenger RNA (mRNA) from these cells was harvested using Trizol (Thermo Fisher Scientific, Waltham, MA, USA) and gene expression for PER1 [18, 19] was quantified using quantitative polymerase chain reaction (qPCR). This experiment was performed in triplicate and repeated once using human primary macrophages.
Quantitative reverse transcriptase PCR
RNA was isolated using the RNeasy kit following the manufacturer's instructions (Qiagen, Hilden, Germany). The creation of complementary DNA (cDNA) was achieved with the M-MLV First-Strand Synthesis system (Invitrogen). Gene expression levels were determined using IQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA).
Activity of liposomes in vitro
Pro-and anti-inflammatory macrophages were activated using lipopolysaccharide (LPS; 100 ng/mL; InvivoGen, San Diego, CA, USA) and interferon c (IFN-c; 10 ng/mL; PeproTech, Rocky Hill, NJ, USA). Treatment occurred with control medium (untreated), empty liposomes (equal volume to liposomal prednisolone), prednisolone (10 mg/mL) or liposomal prednisolone (10 mg/mL) (n ¼ 3). Protein levels of IL-6 and interleukine 10 (IL-10) were measured by means of PeliKine ELISA kits (Sanquin, Amsterdam, The Netherlands).
Animals
The 8-week-old male LEW/HanHsd rats were obtained from Harlan (Harlan Laboratories, Horst, The Netherlands) and housed in individually ventilated cages with unrestricted access to water and standard chow. During experiments the rats were monitored for general welfare daily and cared for in accordance with the guidelines set by the Institutional Committee for Animal Welfare. All experiments were performed with the ethical approval of the Institutional Committee for Animal Welfare at Leiden University Medical Center (DEC number 14124).
Induction of IRI
Rats were subjected to 45 min clamping of the renal artery and vein of the left kidney and injected with Alexa Fluor 750-labelled liposomes, 10 mg/kg liposomal prednisolone, 10 mg/kg prednisolone or an equal volume of empty liposomes or saline. After 96 h, rats were anesthetized and exsanguinated via intracardiac perfusion. 
Real-time near-infrared (NIR) imaging system
After termination, internal organs were imaged using a prototype of the FLARE (fluorescence-assisted resection and exploration) Near Infra Red (NIR) imaging system to measure NIR fluorescence signals.
Quantification of the infiltrate
The presence of macrophages and anti-inflammatory macrophages, granulocytes, myeloid cells, T cells, podocytes, endothelial cells or liposomes in the tissue was determined using immunohistochemistry. The mRNA expression of IL-6, monocyte chemoattractant protein-1 (MCP-1) and tumour necrosis factor-a (TNF-a) was determined using qPCR.
HPLC for liposomal prednisolone
Blood samples were taken before surgery and at 2 h and at Days 1, 2, 3 and 4 after treatment. The concentration of liposomes was assayed with an high-performance liquid chromatography (HPLC) method. The detection limit of the method was 20 ng/mL.
Statistical analysis
All results were analysed using IBM SPSS Statistics 23 software (IBM, Armonk, NY, USA) with either a Student's t-test or one-way ANOVA (post hoc testing with Dunnet, using the saline treatment as a reference group). Only the non-parametric testing of variances occurred with Graphpad Prism 6 software (GraphPad, Software La Jolla, CA, USA) using Dunn's post hoc FIGURE 3: Activation of the GR in macrophages after stimulation with liposomal prednisolone. (A) RAW 264.7 macrophages that were untreated (left), treated with 10 lg/mL prednisolone (middle) or 10 lg/mL liposomal prednisolone (right) were stained for GR (green). Their nuclei were visualized with DAPI (blue). All pictures were taken at Â63 magnification and are presented with a scale bar of 50 mm. The inserts (right bottom corner) show an additional Â2.5 magnification. (B) mRNA upregulation of the GC-responsive gene PER1 was quantified by reverse transcription polymerase chain reaction. Data points are presented as the mean 6 SD of the fold change to the untreated control. *P > 0.05.
testing. All results are displayed as mean 6 SD. A P-value <0.05 was considered statistically significant.
Extended materials and methods can be found in the supplementary text.
R E S U L T S
Uptake of liposomes by macrophage subsets but not by non-phagocytic cells
To evaluate the uptake of liposomes by different macrophage subsets, we polarized primary human monocytes towards proor anti-inflammatory macrophages using granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF), respectively [20] . Both types of macrophages showed a high degree of viability after differentiation (Supplementary data, Figure 1c Fluorescent microscopy revealed that both pro-and antiinflammatory macrophages were able to internalize liposomes. The first signs were visible at 8 h after exposure and further accumulated over time. Especially at later time points, there was a preferential uptake by the anti-inflammatory macrophages ( Figure 1A ). At 24 hours the extent of liposomal uptake was quantified by FACS (Figure 1b) , which showed positive signal in both pro-and anti-inflammatory macrophages. The most abundant signal increase of Alexa Fluor 750 liposomes was observed in the anti-inflammatory macrophages [78.25 6 28.25 vs 46.29 6 19.12; P ¼ 0.02; presented as the treated:untreated mean fluorescence intensity (MFI) ratio] ( Figure 1C ). In contrast, liposomes were not internalized by non-phagocytic HUVECs, HK2 or THP-1 cells (Figure 2 ) after 24 h of incubation, indicating that liposomal uptake was specific for macrophages.
Activation of the GR by prednisolone and liposomal prednisolone
To determine the functional consequence of the uptake of liposomal prednisolone, the activation status of the GR was determined using the RAW 264.7 mouse macrophages and human pro-inflammatory macrophages. The translocation of the receptor from the cytosol to the nucleus was shown in the RAW 264.7 macrophages after 20 h of exposure to liposomal prednisolone and 12 h of exposure to prednisolone in triplicate experiments ( Figure 3A) . A similar translocation was shown using human pro-inflammatory macrophages (Supplementary data, Figure 2a) . Additionally, the upregulation of GC-responsive genes in RAW 264.7 mouse macrophages was evaluated. The mRNA for the GC-responsive gene PER1 was upregulated after incubation of RAW 264.7 macrophages with prednisolone or liposomal prednisolone when compared to saline or liposomal incubation ( Figure  3B ). When repeated in human primary pro-inflammatory macrophages, this upregulation of PER1 was also observed (Supplementary data, Figure 2b ).
Anti-inflammatory effects of liposomal prednisolone on macrophages
Human pro-inflammatory macrophages showed a marked increase in IL-6 protein synthesis after stimulation with LPS and IFN-c (Supplementary data, Figure 1f and g). Importantly, both prednisolone and liposomal prednisolone were able to significantly reduce this LPS/IFN-c-induced IL-6 synthesis in a dose-dependent manner ( Figure 4A ). In these experiments, free prednisolone was more potent in the lower dose range. Conversely, production of IL-10 by anti-inflammatory macrophages was unaffected by the various treatment conditions ( Figure 4B ).
Local accumulation of liposomes in IRI in the rat kidney
To investigate the biodistribution of liposomes in the context of an inflamed kidney, Alexa Fluor 750-labelled liposomes were intravenously injected directly after induction of IRI. At 96 h, rats were sacrificed and several organs were monitored for fluorescence ( Figure 5A ). No liposomes could be detected in blood samples when imaged with the FLARE system (data not shown). The MFI of these organs was quantified in a ratio to brain tissue ( Figure 5B ). It showed that accumulation of Importantly, kidney was also positive, and in a direct comparison with the contralateral kidney of the same animal, the IRI kidney showed a significantly higher kidney:brain MFI ratio ( Figure 5C ).
To gain better insight into the local distribution within the kidney, sections were stained for liposomes, making use of the polyethylene glycol (PEG) moiety, and macrophages. Microscopic examination of the renal tissue revealed that in the contralateral kidney, liposomes accumulate focally in the glomeruli ( Figure 6A ) and the medulla ( Figure 6C ), but not in the corticomedullary region ( Figure 6B ). However, in the kidney subjected to IRI, liposomes still accumulate in the glomeruli ( Figure 6D ), but also co-localize with the macrophages that are present (arrows in Figure 6D ). Additionally, in the corticomedullary region ( Figure 6E ) liposomes are present in a very diffuse pattern and also co-localize with macrophages. We found no indications that liposomes are present in the tubuli, although it should be noted that a lot of these cells have been lost as a consequence of the IRI. In the medullary region ( Figure 6F ) the liposomes are present in a more diffuse pattern than observed in the contralateral kidney. At higher magnification, co-localization of liposomes was observed in the endothelial cells but not in the podocytes of the glomeruli of the kidney subjected to IRI ( Figure 6G and H). Microscopic examination of the spleen revealed that macrophages were exclusively found in co-localization with liposomes ( Figure 6I ).
Shifting the local inflammatory profile with liposomal prednisolone
Following injection of the different compounds for treatment, blood was taken at several time points to evaluate the half-life of liposomes in the circulation. Using HPLC, the plasma half-life of liposomal prednisolone 6 h ( Figure 7 ) after a bolus injection of 10 mg/kg was determined to be 43. This exceeds the maximum serum concentration of prednisolone, which was previously shown to be <2 h [21] . After 96 h, when neither prednisolone nor liposomal prednisolone was detectable in the circulation, the kidneys subjected to IRI showed a marked increase in KIM-1 protein expression in the corticomedullary region when compared with the contralateral kidney (data not shown). The increase of KIM-1-positive tissue indicates substantial damage after induction of IRI. The infiltrate of myeloid cells was rich in macrophages (4.2 6 1.6 area %), with granulocyte presence as well (2.9 6 2.6 area %) ( Figure 8A and B) .
Study of the inflammatory profile in the kidney revealed a decrease of MCP-1 mRNA in animals treated with liposomal prednisolone and prednisolone when compared with untreated 
D I S C U S S I O N
In the present study we show that macrophages are able to internalize a liposomal formulation of prednisolone, leading to translocation of the GR and reduction of IL-6 synthesis. In the rat IRI model, liposomes accumulate at the site of renal inflammation, resulting in a shift towards a less pro-inflammatory state in the kidney.
When tailoring treatment to specific conditions and organs, liposomal encapsulation can be uniquely qualified to facilitate local drug delivery, as is reviewed by Brede et al. [22] . The main Representative image of the spleen of an animal subjected to renal IRI stained for PEG (green), macrophages (red) and nuclei (blue). Pictures A-F and I were taken at Â20 magnification and are presented with a scale bar of 100 mm. Pictures G and H were taken at Â100 magnification and are presented with a scale bar of 10 mm. benefits of local treatment using liposomes are the minimal invasive administration, the time to treatment with off-the-shelf availability and local accumulation in inflamed organs through extravasation in hyperpermeable areas by which off-target exposure is reduced and a potentially lower dose can be administered.
Our studies revealed that liposomes are readily internalized by both pro-and anti-inflammatory macrophages. This observation is supported by other studies utilizing several compositions of liposomal prednisolone, which show co-localization of liposomes and macrophages in inflamed tissues [23, 24] . Also, the current study shows substantial splenic co-localization of liposomes and macrophages, indicating that the minimal colocalization of macrophages and liposomes in the kidney is likely due to limited interaction of interstitial macrophages and extravasated liposomes rather than the inability of macrophages to take up the liposomes.
In the inflamed kidney, liposomes are present in the corticomedullary region and the glomeruli, indicating that treatment of inflammatory conditions that affect the microvasculature of the glomeruli or the corticomedullary region is a promising therapeutic strategy. In particular, conditions that are traditionally treated with high-dose prednisolone, such as glomerulonephritis and acute cellular allograft, could benefit from treatment with liposomal prednisolone. It is very difficult to determine the exact route by which the liposomes accumulate in these regions, either through glomerular filtration and resorption by the epithelium in the proximal tubuli, or interstitial uptake and macrophage processing after leakage from peritubular capillaries. However, microscopic examination showed liposomes to be present mainly on the epithelial side of the glomerular basement membrane and not in the podocytes, as well as in the interstitium of the corticomedullary region, where vascular damage and macrophage influx is prominent, indicating the latter route of accumulation to be the more likely option.
Liposomes were also present in other organs such as the spleen and liver. In these organs both resident macrophages and sinusoidal vasculature were present, which can lead to the liposomal passage of the endothelial cell layer of the blood vessel in the absence of an inflammatory process. This effect is also seen in other studies utilizing nanoparticles to facilitate local therapy [15, [24] [25] [26] [27] . In evaluating the safety profile of liposomal prednisolone, some side effects, such as minimal lymphoid depletion, were observed but did not affect the positive safety profile of this formulation [25] . Other options to facilitate local release from liposomes include stimulation by magnetism or ultrasound [28] . When designing clinical studies using liposomal preparations, the possibility that liposomes accumulate at sites other than the target organ should be taken into account when determining the dosage for treatment since local accumulation of these liposomes will lead to a local increase of GC availability.
Direct exposure of macrophages to liposomes led to translocation of the GR and a subsequent reduction in pro-inflammatory cytokine production despite the characteristic pro-inflammatory effect of nanoparticles on macrophages [29] , which was previously also shown in mouse macrophages treated with liposomal prednisolone [24] . The mechanism by which liposomal prednisolone exerts this effect remains unclear, but several theories, such as direct cell death through toxicity, sustained release through intracellular depots or changing the cellular inflammatory profile, have been suggested [30, 31] .
In vivo, liposomal prednisolone increased the number of anti-inflammatory macrophages and led to a reduction in MCP-1 mRNA expression. Although it is unclear whether a reduction in MCP-1 led to a switch in macrophage polarity or vice versa, a decrease in MCP-1 has been shown to be beneficial in inflammatory diseases in both animal models and human inflammatory disease through reducing the presence of several types of myeloid cells in the inflamed tissue [32] [33] [34] . In contrast to the observation of protein levels in vitro, IL-6 mRNA was unaffected in vivo. In previous studies, proximal tubule epithelial cells appeared unresponsive to corticosteroids [35] , which might explain the inability of prednisolone to affect the production of this pro-inflammatory cytokine in vivo. Together the effects on the macrophage population in vitro and in vivo indicate that liposomal prednisolone appears to shift the local inflammatory profile in the kidney. In line with this, liposomal prednisolone was effective in reducing inflammation in other experimental models of arthritis and vascular inflammation [15, 16, 25] . In the current model, the effect on the total content of inflammatory cells was minimal, which was expected since treatment of IRI using GCs is only marginally effective in a pretreatment setting [36] [37] [38] . The functional effect of liposomal prednisolone on the inflamed kidney is currently being evaluated in a mouse model of acute renal allograft rejection.
In conclusion, we show that systemic delivery of liposomal prednisolone results in local accumulation in the inflamed kidney and a shift towards anti-inflammatory macrophages, which is accompanied by reduced production of pro-inflammatory cytokines. Liposomal encapsulation is therefore a promising strategy for targeted delivery of GCs to the inflamed kidney.
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